Innovent Biologics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IVBXF | ROIV | INCY | GMAB | IDYA | LGND | |
|---|---|---|---|---|---|---|
| Market cap | 21.80B | 24.22B | 22.92B | 22.75B | 3.17B | 5.89B |
| P/E (TTM) | 125.0 | — | 14.4 | 29.1 | — | 31.1 |
| Forward P/E | — | -19.5 | 13.0 | 24.4 | -7.9 | 24.7 |
| Price/book | 7.0 | 5.7 | 3.6 | 3.7 | 2.6 | 6.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.94% | +89.01% | +31.22% | +21.15% | +7.67% | +58.26% |
| Today | 0.00% | −1.50% | −0.18% | −2.17% | −2.95% | −0.99% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IVBXF news ›Innovent Biologics announces approval of SYCUME in China for thyroid eye disease
The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug. Innovent Biologics announced the approval of SYCUME, a recombinant…
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize... - Under the terms of the agreement, Spero will receive exclusive global rights,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
prnewswire.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.